Key Points – Medline reported strong second-quarter growth, with net sales up 12% to $7.7 billion, led by a 16% increase in Supply Chain Solutions and a 15% increase in U.S. acute-care sales.
The company raised its full-year organic sales growth outlook to 9%-10%. – Adjusted EBITDA rose 13% to $1.1 billion, boosted by a $243 million tariff-refund benefit, but underlying profitability faced higher costs, quality remediation, retail weakness and operational investments
Medline lowered full-year adjusted EBITDA guidance to $3.3 billion-$3.4 billion from $3.5 billion-$3.6 billion. – A June fire at the Tracy, California, distribution center reduced first-half net income by $336 million, though Medline limited customer disruption and is expanding its California distribution network. The company expects an additional $50 million-$100 million in Tracy-related costs during the second half. – A Fresh IPO That Long-Term Investors Shouldn’t Ignore Medline (NASDAQ:MDLN) reported second-quarter 2026 net sales growth of 12% to $7.7 billion, supported by demand across its medical-surgical product and supply-chain businesses, while raising its full-year organic sales outlook. The company also lowered its adjusted EBITDA guidance, citing operational investments, quality remediation efforts, retail weakness, Middle East-related inflation and costs associated with a June fire at its Tracy, California distribution center.
Chief Executive Officer Jim Boyle said Medline Brand sales grew 7% during the quarter, including the effect of customer repayments tied to IEEPA tariff refunds, while Supply Chain Solutions sales rose 16% on new customer implementations and growth among existing customers. He said the supply-chain segment remains important to Medline’s strategy because it can create opportunities to convert customer spending toward higher-margin Medline Brand products. “We are pleased with the continued momentum across the business and are raising our fiscal year organic sales…